Drug intelligence / Profile preview

VYR-304

Development stage: Preclinical
Lead developer: Vyripharm International
Modality: Small Molecules

Overview

VYR-304 is a small molecule therapeutic candidate being developed by Vyripharm International. It specifically targets the cannabinoid receptor 1 (CB1) and is intended for the treatment of various neurologic disorders. As of the latest pipeline updates, the drug is in the IND-enabling phase of development. Vyripharm focuses on integrating cannabinoid-based medicine with precision medicine and diagnostic imaging to improve patient outcomes in neurology and other therapeutic areas.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on VYR-304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VYR-304.

Explore the full profile